Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Merck & Co
(NY:
MRK
)
117.46
+0.06 (+0.05%)
Official Closing Price
Updated: 7:00 PM EDT, Aug 29, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Press Releases about Merck & Co
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Merck to Participate in the Morgan Stanley 22nd Annual Global Healthcare Conference
Today 6:45 EDT
From
Merck & Co., Inc.
Via
Business Wire
Merck Provides Update on Phase 3 KEYNOTE-867 and KEYNOTE-630 Trials
Today 6:30 EDT
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Phase 3 Trial Initiation for Bomedemstat, an Investigational Candidate for the Treatment of Certain Patients With Essential Thrombocythemia
August 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives European Commission Approval for WINREVAIR™ (sotatercept) in Combination With Other Pulmonary Arterial Hypertension (PAH) Therapies, for the Treatment of PAH in Adult Patients With Functional Class II-III
August 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
MarketBeat Week in Review – 8/19 - 8/23
August 24, 2024
Stocks closed the week higher on the near certainty that the Fed will cut interest rates in September, but in the short term, all eyes are on NVDA earnings
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
Merck's Stock Dip Offers a Buying Opportunity: Here’s Why
August 20, 2024
Global big pharmaceutical company Merck & Co. Inc. (NYSE: MRK) shares sank 9% following its Q2 2024 earnings release. Merck beat top and bottom line estimates,
Via
MarketBeat
Topics
Intellectual Property
Exposures
Intellectual Property
Moderna Dips on Q2 Earnings But Can It Rip on a Short Squeeze?
August 19, 2024
Biotechnology company Moderna Inc. (NASDAQ: MRNA) stock rocked investors with a 30% drop following its second-quarter 2024 earnings release.
Via
MarketBeat
Exposures
COVID-19
Product Safety
Merck to Acquire Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical
August 09, 2024
From
Merck & Co., Inc.
Via
Business Wire
BioMedNewsBreaks — Annovis Bio Inc. (NYSE: ANVS) Reports on ‘Synergistic Effect’ of Lead Compound Plus GLP-1 in AD Treatment Model
August 08, 2024
Via
Investor Brand Network
Merck Provides Update on Phase 3 KeyVibe-008 Trial Evaluating an Investigational Fixed-Dose Combination of Vibostolimab and Pembrolizumab in Patients With Extensive-Stage Small Cell Lung Cancer
August 08, 2024
From
Merck & Co., Inc.
Via
Business Wire
Alzheimer’s Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
EQNX::TICKER_START (NYSE:ANVS),(NYSE:MRK),(NASDAQ:SNY),(NYSE:JNJ),(NYSE:NVS) EQNX::TICKER_END
Via
FinancialNewsMedia
Daiichi Sankyo and Merck Enter into Global Development and Commercialization Agreement for MK-6070
August 06, 2024
From
Daiichi Sankyo
Via
Business Wire
MarketBeat Week in Review – 7/29 - 8/2
August 03, 2024
The tech-led sell-off expanded and accelerated to close the week; more volatility may be the norm for the rest of the summer, which may force the Fed to move
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Alzheimer's Disease Diagnostics & Therapeutics Market Driven by Use of Biomarkers and Advancing R&D Activities
August 06, 2024
From
FN Media Group LLC
Via
GlobeNewswire
IDeate-Lung02 Phase 3 Trial of Ifinatamab Deruxtecan Initiated in Patients with Relapsed Small Cell Lung Cancer
August 01, 2024
From
Daiichi Sankyo
Via
Business Wire
Pharma Stock Cuts Earnings Outlook: Still a Buying Opportunity
July 30, 2024
Merck stock is down more than 4% after lowering its 2024 earnings outlook, but if you look beyond the headline numbers, this could be a chance to buy the dip
Via
MarketBeat
Merck Announces Second-Quarter 2024 Financial Results
July 30, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Padcev® (enfortumab vedotin-ejfv) as First-Line Treatment for Patients With Unresectable or Metastatic Urothelial Carcinoma
July 26, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Fourth-Quarter 2024 Dividend
July 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Announces Topline Results from Phase 2b/3 Trial of Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus Preventative Monoclonal Antibody for Infants
July 23, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck to Share New Research and Host Community-Focused Symposia at AIDS 2024
July 16, 2024
From
Merck & Co., Inc.
Via
Business Wire
Positive News is Driving This Cancer Drug Maker’s Stock Higher
July 15, 2024
IDEAYA Biosciences stock is up more than 16% on positive treatment data in a Phase 2 clinical trial, but after a 76% run-up, IDYA stock may need a breather
Via
MarketBeat
Merck Completes Acquisition of EyeBio
July 12, 2024
From
Merck & Co., Inc.
Via
Business Wire
Teva Pharmaceuticals Stock: Unlock Value in This Generic Drug Gem
July 10, 2024
Drug prices continue to rise, driving up healthcare costs. Pharmaceutical companies usually hike drug prices at the beginning of each year. In January 2024
Via
MarketBeat
Merck Animal Health Completes Acquisition of Elanco’s Aqua Business
July 09, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck and Orion Announce Mutual Exercise of Option Providing Merck Global Exclusive Rights to Opevesostat, an Investigational CYP11A1 Inhibitor, for the Treatment of Metastatic Castration-Resistant Prostate Cancer
July 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck to Hold Second-Quarter 2024 Sales and Earnings Conference Call July 30
July 01, 2024
From
Merck & Co., Inc.
Via
Business Wire
Merck Receives Positive EU CHMP Opinion for WINREVAIR™ (sotatercept) in Pulmonary Arterial Hypertension (PAH)
June 28, 2024
From
Merck & Co., Inc
Via
Business Wire
CDC’S ACIP Unanimously Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Appropriate Adults
June 27, 2024
From
Merck & Co., Inc.
Via
Business Wire
Patritumab Deruxtecan BLA Submission Receives Complete Response Letter from FDA Due to Inspection Findings at Third-Party Manufacturer
June 26, 2024
From
Daiichi Sankyo
Via
Business Wire
< Previous
1
2
3
4
5
6
7
8
9
...
18
19
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.